© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Twist Bioscience Corporation (TWST) stock declined over -3.29%, trading at $140.80 on NASDAQ, down from the previous close of $145.59. The stock opened at $145.00, fluctuating between $137.37 and $145.41 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | 145.37 | 145.41 | 137.37 | 140.80 | 1.8M |
| Aug 21, 2026 | 138.43 | 145.93 | 135.05 | 145.59 | 1.79M |
| Aug 20, 2026 | 136.84 | 145.51 | 135.17 | 136.33 | 2.39M |
| Aug 19, 2026 | 128.00 | 142.84 | 127.75 | 142.39 | 3.55M |
| Aug 18, 2026 | 121.61 | 123.30 | 115.28 | 116.10 | 1.27M |
| Aug 17, 2026 | 116.91 | 124.98 | 116.91 | 124.41 | 977K |
| Aug 14, 2026 | 124.09 | 124.71 | 118.44 | 118.57 | 1.14M |
| Aug 13, 2026 | 126.22 | 126.40 | 122.14 | 125.29 | 912K |
| Aug 12, 2026 | 123.96 | 125.38 | 120.50 | 125.21 | 1.61M |
| Aug 11, 2026 | 125.63 | 125.63 | 120.65 | 123.12 | 1.06M |
| Aug 10, 2026 | 113.56 | 125.66 | 113.18 | 124.88 | 2.54M |
| Aug 07, 2026 | 110.89 | 118.32 | 109.26 | 115.67 | 1.56M |
| Aug 06, 2026 | 113.76 | 113.76 | 108.62 | 109.08 | 1.83M |
| Aug 05, 2026 | 104.50 | 115.56 | 104.49 | 115.01 | 3.29M |
| Aug 04, 2026 | 106.58 | 106.58 | 98.89 | 99.45 | 1.24M |
| Aug 03, 2026 | 81.60 | 102.34 | 80.59 | 101.06 | 2.94M |
| Jul 31, 2026 | 93.07 | 93.57 | 88.30 | 91.55 | 1.49M |
| Jul 30, 2026 | 87.75 | 91.92 | 86.50 | 91.33 | 1.66M |
| Jul 29, 2026 | 87.41 | 89.19 | 82.80 | 85.47 | 1.46M |
| Jul 28, 2026 | 85.45 | 88.65 | 82.92 | 88.55 | 1.41M |
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
| Employees | 979 |
| Beta | 2.16 |
| Sales or Revenue | $376.57M |
| 5Y Sales Change% | 1.739% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |